With the help of its current investor, Fireside Ventures, and Susquehanna Asia Venture Capital, the VC division of Susquehanna International Group, the gut health startup The Good Bug has raised Rs 100 crore, or roughly $12 million, in a Series B funding round.
In 2024, the Mumbai-based startup had previously raised $4 million in a Series A extension led by Sharrp Ventures, the family office of Harsh Mariwala of the Marico Group. With the most recent fundraising effort, it now has about $20 million in total funding.
As stated in a press release, The Good Bug plans to use the money to increase research and development in the field of microbiome science, scale clinical trials, increase distribution, and raise brand awareness among consumers and medical professionals.
The Good Bug, which was co-founded in 2022 by Keshav Biyani and Prabhu Karthikeyan, creates probiotics and gut-focused health products that focus on immunity, metabolism, and digestion. Metabolically Lean, a GLP-1-based formulation that the startup recently unveiled, is promoted as a natural, non-invasive substitute for weight-loss medications like Ozempic and Mounjaro. According to the brand, the product improves metabolism and reduces appetite by naturally raising GLP-1 levels.
“The main deployment of these funds will be towards accelerating innovation in microbiome science and bacterial research.” We’ll continue investing in clinical trials, brand building, and hiring top-tier talent across research, science, and business,” said Keshav Biyani, co-founder of The Good Bug.
